Javascript must be enabled to continue!
Recommendations of the Polish Zebrafish Society on the use of the zebrafish (Danio rerio) model in biomedical research
View through CrossRef
The zebrafish (
Danio rerio
) has become a widely adopted vertebrate model in biomedical research, offering high translational value while supporting the principles of Replacement, Reduction, and Refinement (3Rs). Here, the Polish Zebrafish Society presents comprehensive, field-specific recommendations for the responsible and effective use of zebrafish across major areas of biomedical research. The document summarizes the scientific rationale and experimental advantages of zebrafish-based approaches in oncology, toxicology, neurology and neuropsychiatry, metabolic diseases, immunology, cardiology, and genetic disease modelling. The model’s key strengths include rapid development, optical transparency, genetic tractability, and strong conservation of molecular and physiological pathways relevant to human disease. These features enable real-time
in vivo
analysis of pathological processes, high-throughput pharmacological and toxicological screening, and functional validation of disease-associated genes. By integrating ethical considerations with robust experimental evidence, these recommendations aim to promote standardized implementation of zebrafish models in academic research, pharmaceutical development, and regulatory science. Broad adoption of zebrafish-based approaches can accelerate preclinical discovery, enhance translational relevance, and substantially reduce reliance on higher vertebrate models.
Title: Recommendations of the Polish Zebrafish Society on the use of the zebrafish (Danio rerio) model in biomedical research
Description:
The zebrafish (
Danio rerio
) has become a widely adopted vertebrate model in biomedical research, offering high translational value while supporting the principles of Replacement, Reduction, and Refinement (3Rs).
Here, the Polish Zebrafish Society presents comprehensive, field-specific recommendations for the responsible and effective use of zebrafish across major areas of biomedical research.
The document summarizes the scientific rationale and experimental advantages of zebrafish-based approaches in oncology, toxicology, neurology and neuropsychiatry, metabolic diseases, immunology, cardiology, and genetic disease modelling.
The model’s key strengths include rapid development, optical transparency, genetic tractability, and strong conservation of molecular and physiological pathways relevant to human disease.
These features enable real-time
in vivo
analysis of pathological processes, high-throughput pharmacological and toxicological screening, and functional validation of disease-associated genes.
By integrating ethical considerations with robust experimental evidence, these recommendations aim to promote standardized implementation of zebrafish models in academic research, pharmaceutical development, and regulatory science.
Broad adoption of zebrafish-based approaches can accelerate preclinical discovery, enhance translational relevance, and substantially reduce reliance on higher vertebrate models.
Related Results
619. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Epetraborole Dose Selection for the Treatment of Patients with Mycobacterium avium Complex (MAC) Lung Disease
619. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Epetraborole Dose Selection for the Treatment of Patients with Mycobacterium avium Complex (MAC) Lung Disease
Abstract
Background
Epetraborole (EBO) is an orally available, bacterial leucyl transfer RNA synthetase inhibitor that concentra...
LB2306. Population Pharmacokinetic (PPK), Pharmacokinetic/Pharmacodynamic attainment (PTA), and Clinical Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Sulbactam-Durlobactam (SUL-DUR) to Support Dose Selection for the Treatment of Acinetobacter baum
LB2306. Population Pharmacokinetic (PPK), Pharmacokinetic/Pharmacodynamic attainment (PTA), and Clinical Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Sulbactam-Durlobactam (SUL-DUR) to Support Dose Selection for the Treatment of Acinetobacter baum
Abstract
Background
SUL-DUR is a β-lactam/β-lactamase inhibitor combination in development for the treatment of ABC infections, ...
The genome sequences of Danio albolineatus (Blyth, 1860), Danio choprai Hora, 1928, Danio jaintianensis (Sen, 2007) and Danio tinwini [Kullander & Fang], 2009
The genome sequences of Danio albolineatus (Blyth, 1860), Danio choprai Hora, 1928, Danio jaintianensis (Sen, 2007) and Danio tinwini [Kullander & Fang], 2009
We present the scaffold-level genome assemblies of four
Danio
species, released in 2020:
Danio albolineatus, Danio chopr...
Signaling pathways involved in tooth development: why use zebrafish in dental research?
Signaling pathways involved in tooth development: why use zebrafish in dental research?
Zebrafish (Danio rerio, formerly named Brachydanio rerio) is an established model organism used in health research for a long time. In the past decades, some research groups have b...
Alternatives in Animal Research: The Zebrafish Option
Alternatives in Animal Research: The Zebrafish Option
The utilisation of animals in scientific research has been a longstanding subject of debate, with concerns about animal welfare and ethics. In response, researchers have been inves...
Abstract 1273: Adaptive immunity in a zebrafish model of melanoma.
Abstract 1273: Adaptive immunity in a zebrafish model of melanoma.
Abstract
The recent success of the anti-CLTA-4 antibody, ipilimumab, for late stage metastatic melanoma, provides proof of principle that stimulating the immune syst...
Toxicity and teratogenicity evaluation of hydroethanolic extract of momordica charantia fruit using zebrafish (DANIO RERIO) embryos model
Toxicity and teratogenicity evaluation of hydroethanolic extract of momordica charantia fruit using zebrafish (DANIO RERIO) embryos model
The use of zebrafish vertebrate model in vivo analysis of the drug toxicity and efficacy, chemical toxicity, and safety is increasing in recent researches. Momordica charantia Lin...
593. Population Pharmacokinetic Model Development for Epetraborole and Mycobacterium avium Complex (MAC) Lung Disease Patients Using Data from Phase 1 and 2 Studies
593. Population Pharmacokinetic Model Development for Epetraborole and Mycobacterium avium Complex (MAC) Lung Disease Patients Using Data from Phase 1 and 2 Studies
Abstract
Background
Epetraborole (EBO), an orally available bacterial leucyl transfer RNA synthetase inhibitor with potent activ...

